DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Tributylchlorostannane

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
LTEA_HepaRG_ABCB1	Liver	Human	5243	ABCB1	Activatory	3.21 μM
LTEA_HepaRG_ABCC2	Liver	Human	1244	ABCC2	Inhibitory	3.8 μM
LTEA_HepaRG_ABCG2	Liver	Human	9429	ABCG2	Inhibitory	4.6 μM
LTEA_HepaRG_ACOX1	Liver	Human	51	ACOX1	Inhibitory	3.11 μM
LTEA_HepaRG_ALPP	Liver	Human	250	ALPP	Activatory	4.3 μM
LTEA_HepaRG_BCL2	Liver	Human	596	BCL2	Activatory	3.08 μM
LTEA_HepaRG_BCL2L11	Liver	Human	10018	BCL2L11	Activatory	12.86 μM
LTEA_HepaRG_CCND1	Liver	Human	595	CCND1	Activatory	81.18 μM
LTEA_HepaRG_CDKN1A	Liver	Human	1026	CDKN1A	Activatory	88.05 μM
LTEA_HepaRG_CFLAR	Liver	Human	8837	CFLAR	Activatory	4.12 μM
LTEA_HepaRG_CYP3A5	Liver	Human	1577	CYP3A5	Inhibitory	82.83 μM
LTEA_HepaRG_EGF	Liver	Human	1950	EGF	Inhibitory	32.41 μM
LTEA_HepaRG_EGR1	Liver	Human	1958	EGR1	Inhibitory	50.0 μM
LTEA_HepaRG_FASN	Liver	Human	2194	FASN	Activatory	2.86 μM
LTEA_HepaRG_FOXO1	Liver	Human	2308	FOXO1	Activatory	18.76 μM
LTEA_HepaRG_GADD45A	Liver	Human	1647	GADD45A	Activatory	50.0 μM
LTEA_HepaRG_GADD45G	Liver	Human	10912	GADD45G	Inhibitory	5.56 μM
LTEA_HepaRG_GCLC	Liver	Human	2729	GCLC	Inhibitory	50.0 μM
LTEA_HepaRG_HGF	Liver	Human	3082	HGF	Inhibitory	50.0 μM
LTEA_HepaRG_IGF1	Liver	Human	3479	IGF1	Inhibitory	14.33 μM
LTEA_HepaRG_IL6	Liver	Human	3569	IL6	Activatory	2.73 μM
LTEA_HepaRG_IL6R	Liver	Human	3570	IL6R	Inhibitory	50.0 μM
LTEA_HepaRG_JUN	Liver	Human	3725	JUN	Inhibitory	3.32 μM
LTEA_HepaRG_KCNK1	Liver	Human	3775	KCNK1	Inhibitory	2.85 μM
LTEA_HepaRG_MIR122	Liver	Human	406906	MIR122	Inhibitory	16.18 μM
LTEA_HepaRG_NFKB1	Liver	Human	4790	NFKB1	Inhibitory	9.07 μM
LTEA_HepaRG_NQO1	Liver	Human	1728	NQO1	Inhibitory	15.81 μM
LTEA_HepaRG_SDHB	Liver	Human	6390	SDHB	Inhibitory	50.0 μM
LTEA_HepaRG_STAT3	Liver	Human	6774	STAT3	Inhibitory	15.27 μM
LTEA_HepaRG_TGFA	Liver	Human	7039	TGFA	Activatory	50.0 μM
LTEA_HepaRG_THRSP	Liver	Human	7069	THRSP	Inhibitory	2.84 μM
LTEA_HepaRG_TNFRSF1A	Liver	Human	7132	TNFRSF1A	Activatory	50.0 μM
LTEA_HepaRG_TP53	Liver	Human	7157	TP53	Inhibitory	12.61 μM
LTEA_HepaRG_UGT1A1	Liver	Human	54658	UGT1A1	Inhibitory	3.12 μM
LTEA_HepaRG_UGT1A6	Liver	Human	54578	UGT1A6	Inhibitory	15.62 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CCTE_Deisenroth_5AR_NBTE_ratio	Kidney	Human	6716	SRD5A2	Inhibitory	20.7 μM
NVS_ENZ_hBACE		Human	23621	BACE1	Loss	3.71 μM
NVS_ENZ_hDUSP3		Human	1845	DUSP3	Loss	6.23 μM
NVS_ENZ_hMMP7		Human	4316	MMP7	Loss	12.57 μM
NVS_ENZ_hSIRT1		Human	23411	SIRT1	Loss	9.94 μM
NVS_ENZ_rACFSKBinding	Brain	Rat	64532	Adcy5	Loss	41.04 μM
NVS_GPCR_g5HT4	Brain	Guinea pig	100135548	Htr4	Loss	2.92 μM
NVS_GPCR_gBK2	Intestinal	Guinea pig	100135486	Bdkrb2	Loss	11.56 μM
NVS_GPCR_gH2	Brain	Guinea pig	100135540	Hrh2	Loss	3.04 μM
NVS_GPCR_gLTB4	Spleen	Guinea pig	100379538	Ltb4r	Loss	15.81 μM
NVS_GPCR_gMPeripheral_NonSelective	Bladder	Guinea pig	100379235	Chrm3	Loss	9.81 μM
NVS_GPCR_gOpiateK	Brain	Guinea pig	100135587	Oprk1	Loss	14.48 μM
NVS_GPCR_h5HT2A	Brain	Human	3356	HTR2A	Loss	32.64 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	5.51 μM
NVS_GPCR_hAdoRA1	Brain	Human	134	ADORA1	Loss	25.0 μM
NVS_GPCR_hAdoRA2a		Human	135	ADORA2A	Loss	6.43 μM
NVS_GPCR_hAdra2A		Human	150	ADRA2A	Loss	3.65 μM
NVS_GPCR_hAdrb2		Human	154	ADRB2	Loss	5.47 μM
NVS_GPCR_hAdrb3		Human	155	ADRB3	Loss	9.81 μM
NVS_GPCR_hETB		Human	1910	EDNRB	Loss	15.08 μM
NVS_GPCR_hM4		Human	1132	CHRM4	Loss	17.61 μM
NVS_GPCR_hNPY2		Human	4887	NPY2R	Loss	10.22 μM
NVS_GPCR_hV1A		Human	552	AVPR1A	Loss	7.85 μM
NVS_GPCR_mCCKAPeripheral	Pancreas	Mouse	12425	Cckar	Loss	0.23 μM
NVS_GPCR_r5HT_NonSelective	Brain	Rat	24473	Htr1a	Loss	11.97 μM
NVS_GPCR_r5HT1_NonSelective	Brain	Rat	24473	Htr1a	Loss	17.24 μM
NVS_GPCR_rAdra1_NonSelective	Brain	Rat	29412	Adra1a	Loss	8.22 μM
NVS_GPCR_rAdra1A	Brain	Rat	29412	Adra1a	Loss	11.99 μM
NVS_GPCR_rAdra1B	Liver	Rat	24173	Adra1b	Loss	3.87 μM
NVS_GPCR_rAdra2_NonSelective	Brain	Rat	25083	Adra2a	Loss	2.98 μM
NVS_GPCR_rAdrb_NonSelective	Brain	Rat	24925	Adrb1	Loss	25.0 μM
NVS_GPCR_rCRF	Brain	Rat	58959	Crhr1	Loss	3.71 μM
NVS_GPCR_rGalanin	Brain	Rat	50577	Galr1	Loss	3.99 μM
NVS_GPCR_rH3	Brain	Rat	85268	Hrh3	Loss	15.13 μM
NVS_GPCR_rmMGluR5	Brain	Rat	24418	Grm5	Loss	25.0 μM
NVS_GPCR_rOpiate_NonSelective	Brain	Rat	25601	Oprm1	Loss	3.98 μM
NVS_GPCR_rOpiate_NonSelectiveNa	Brain	Rat	25601	Oprm1	Loss	8.89 μM
NVS_GPCR_rTRH	Brain	Rat	25570	Trhr	Loss	13.66 μM
NVS_GPCR_rVIP_NonSelective	Brain	Rat	24875	Vipr1	Loss	8.75 μM
NVS_IC_hKhERGCh		Human	3757	KCNH2	Loss	3.28 μM
NVS_IC_rCaBTZCHL	Brain	Rat	25398	Cacna1a	Loss	16.22 μM
NVS_IC_rCaDHPRCh_L	Brain	Rat	25398	Cacna1a	Loss	10.97 μM
NVS_IC_rNaCh_site2	Brain	Rat	81574	Scn1a	Loss	17.57 μM
NVS_NR_hPR		Human	5241	PGR	Loss	2.92 μM
NVS_NR_rAR	Prostate	Rat	24208	Ar	Loss	4.33 μM
NVS_TR_gDAT	Brain	Guinea pig	100714898	Slc6a3	Loss	10.14 μM
NVS_TR_hAdoT		Human	2030	SLC29A1	Loss	34.64 μM
NVS_TR_hDAT		Human	6531	SLC6A3	Loss	3.57 μM
NVS_TR_hSERT	Vascular	Human	6532	SLC6A4	Loss	11.36 μM
NVS_TR_rNET	Brain	Rat	83511	Slc6a2	Loss	14.44 μM
NVS_TR_rSERT	Brain	Rat	25553	Slc6a4	Loss	8.33 μM
ATG_C_EBP_CIS	Liver	Human	1051	CEBPB	Activatory	0.1 μM
ATG_DR5_RAR_CIS	Liver	Human	5914\|5915\|5916	RARA\|RARB\|RARG	Inhibitory	0.0 μM
ATG_IR1_CIS	Liver	Human	9971	NR1H4	Inhibitory	0.01 μM
ATG_PPRE_CIS	Liver	Human	5465\|5467\|5468	PPARA\|PPARD\|PPARG	Activatory	0.08 μM
ATG_NURR1_TRANS	Liver	Human	4929	NR4A2	Gain	0.03 μM
ATG_PPARg_TRANS	Liver	Human	5468	PPARG	Gain	0.09 μM
ATG_RXRb_TRANS	Liver	Human	6257	RXRB	Gain	0.01 μM
BSK_3C_Eselectin	Vascular	Human	6401	SELE	Inhibitory	0.15 μM
BSK_3C_HLADR	Vascular	Human	3122	HLA-DRA	Inhibitory	0.15 μM
BSK_3C_ICAM1	Vascular	Human	3383	ICAM1	Inhibitory	0.15 μM
BSK_3C_IL8	Vascular	Human	3576	CXCL8	Inhibitory	0.16 μM
BSK_3C_MCP1	Vascular	Human	6347	CCL2	Inhibitory	0.15 μM
BSK_3C_MIG	Vascular	Human	4283	CXCL9	Inhibitory	0.15 μM
BSK_3C_TissueFactor	Vascular	Human	2152	F3	Inhibitory	0.15 μM
BSK_3C_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	0.15 μM
BSK_3C_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	0.15 μM
BSK_4H_Eotaxin3	Vascular	Human	10344	CCL26	Inhibitory	0.15 μM
BSK_4H_Pselectin	Vascular	Human	6403	SELP	Inhibitory	0.15 μM
BSK_4H_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	0.15 μM
BSK_4H_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	0.15 μM
BSK_BE3C_HLADR	Lung	Human	3122	HLA-DRA	Inhibitory	0.21 μM
BSK_BE3C_IL1a	Lung	Human	3552	IL1A	Inhibitory	0.15 μM
BSK_BE3C_MIG	Lung	Human	4283	CXCL9	Inhibitory	0.16 μM
BSK_BE3C_MMP1	Lung	Human	4312	MMP1	Inhibitory	0.14 μM
BSK_BE3C_PAI1	Lung	Human	5054	SERPINE1	Inhibitory	0.14 μM
BSK_BE3C_TGFb1	Lung	Human	7040	TGFB1	Inhibitory	0.14 μM
BSK_BE3C_tPA	Lung	Human	5327	PLAT	Inhibitory	0.23 μM
BSK_BE3C_uPA	Lung	Human	5328	PLAU	Inhibitory	0.15 μM
BSK_BE3C_uPAR	Lung	Human	5329	PLAUR	Inhibitory	0.14 μM
BSK_CASM3C_LDLR	Vascular	Human	3949	LDLR	Inhibitory	0.23 μM
BSK_CASM3C_SAA	Vascular	Human	6288	SAA1	Inhibitory	0.15 μM
BSK_CASM3C_Thrombomodulin	Vascular	Human	7056	THBD	Inhibitory	3.97 μM
BSK_CASM3C_TissueFactor	Vascular	Human	2152	F3	Inhibitory	0.15 μM
BSK_CASM3C_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	0.15 μM
BSK_hDFCGF_MCSF	Skin	Human	1435	CSF1	Inhibitory	0.15 μM
BSK_hDFCGF_TIMP1	Skin	Human	7076	TIMP1	Inhibitory	0.15 μM
BSK_hDFCGF_VCAM1	Skin	Human	7412	VCAM1	Inhibitory	0.15 μM
BSK_KF3CT_ICAM1	Skin	Human	3383	ICAM1	Inhibitory	0.15 μM
BSK_KF3CT_MCP1	Skin	Human	6347	CCL2	Inhibitory	0.15 μM
BSK_KF3CT_TIMP2	Skin	Human	7077	TIMP2	Inhibitory	0.24 μM
BSK_KF3CT_uPA	Skin	Human	5328	PLAU	Inhibitory	0.15 μM
BSK_LPS_CD40	Vascular	Human	958	CD40	Inhibitory	0.15 μM
BSK_LPS_Eselectin	Vascular	Human	6401	SELE	Inhibitory	0.15 μM
BSK_LPS_IL8	Vascular	Human	3576	CXCL8	Inhibitory	0.15 μM
BSK_LPS_MCP1	Vascular	Human	6347	CCL2	Inhibitory	0.15 μM
BSK_LPS_TissueFactor	Vascular	Human	2152	F3	Inhibitory	0.15 μM
BSK_LPS_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	0.15 μM
BSK_SAg_CD40	Vascular	Human	958	CD40	Inhibitory	0.15 μM
BSK_SAg_CD69	Vascular	Human	969	CD69	Inhibitory	0.15 μM
BSK_SAg_Eselectin	Vascular	Human	6401	SELE	Inhibitory	0.15 μM
BSK_SAg_IL8	Vascular	Human	3576	CXCL8	Inhibitory	0.15 μM
BSK_SAg_MCP1	Vascular	Human	6347	CCL2	Inhibitory	0.15 μM
BSK_SAg_MIG	Vascular	Human	4283	CXCL9	Inhibitory	0.15 μM
NVS_NR_hPPARa		Human	5465	PPARA	Loss	0.02 μM
ATG_hPPARg_XSP1	Liver	Human	5468	PPARG	Gain	0.06 μM
ATG_mPPARg_XSP1	Liver	Human	19016	Pparg	Gain	0.06 μM
ATG_hTRa_XSP1	Liver	Human	7067	THRA	Gain	0.1 μM
ATG_hTRb_XSP1	Liver	Human	7068	THRB	Gain	0.16 μM
CPHEA_Stoker_NIS_Inhibition_RAIU	Kidney	Human	6528	SLC5A5	Loss	8.22 μM
ATG_mPPARg_XSP2	Liver	Human	19016	Pparg	Gain	0.06 μM
ATG_hPPARg_XSP2	Liver	Human	5468	PPARG	Gain	0.06 μM
TOX21_AR_BLA_Agonist_ratio	Kidney	Human	367	AR	Gain	14.71 μM
TOX21_ERa_BLA_Agonist_ratio	Kidney	Human	2099	ESR1	Gain	14.34 μM
TOX21_GR_BLA_Agonist_ratio	Cervix	Human	2908	NR3C1	Gain	13.69 μM
TOX21_PPARg_BLA_Agonist_ratio	Kidney	Human	5468	PPARG	Gain	30.29 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.21 μM
TOX21_RORg_LUC_CHO_Antagonist	Ovary	Chinese hamster	6097	RORC	Loss	0.22 μM
TOX21_AP1_BLA_Agonist_ratio	Cervix	Human	2353\|3725	FOS\|JUN	Gain	12.21 μM
TOX21_TSHR_HTRF_Agonist_ratio	Kidney	Human	7253	TSHR	Gain	0.23 μM
TOX21_TSHR_HTRF_Antagonist_ratio	Kidney	Human	7253	TSHR	Loss	11.38 μM
TOX21_TRHR_HEK293_Agonist	Kidney	Human	7201	TRHR	Gain	6.68 μM
TOX21_TRHR_HEK293_Antagonist	Kidney	Human	7201	TRHR	Loss	3.71 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	16.0 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	12.91 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	40.49 μM
TOX21_hERG_U2OS_Antagonist	Bone	Human	3757	KCNH2	Loss	9.95 μM
TOX21_GNRHR_HEK293_Agonist	Kidney	Human	2798	GNRHR	Gain	16.0 μM
TOX21_KISS1R_HEK293_Agonist	Kidney	Human	84634	KISS1R	Gain	63.21 μM
TOX21_KISS1R_HEK293_WT	Kidney	Human	84634	KISS1R	Gain	37.55 μM
TOX21_AR_BLA_Agonist_ratio	Kidney	Human	367	AR	Gain	27.13 μM
TOX21_ERa_BLA_Agonist_ratio	Kidney	Human	2099	ESR1	Gain	24.49 μM
TOX21_GR_BLA_Agonist_ratio	Cervix	Human	2908	NR3C1	Gain	7.77 μM
TOX21_PPARg_BLA_Agonist_ratio	Kidney	Human	5468	PPARG	Gain	11.72 μM
TOX21_AP1_BLA_Agonist_ratio	Cervix	Human	2353\|3725	FOS\|JUN	Gain	25.43 μM
TOX21_TSHR_HTRF_Antagonist_ratio	Kidney	Human	7253	TSHR	Loss	13.87 μM
TOX21_CAR_LUC_Antagonist	Liver	Human	9970	NR1I3	Loss	0.21 μM
TOX21_TRHR_HEK293_Agonist	Kidney	Human	7201	TRHR	Gain	6.99 μM
TOX21_TRHR_HEK293_Antagonist	Kidney	Human	7201	TRHR	Loss	2.9 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	15.15 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	13.95 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	70.44 μM
TOX21_hERG_U2OS_Antagonist	Bone	Human	3757	KCNH2	Loss	5.94 μM
TOX21_GNRHR_HEK293_Agonist	Kidney	Human	2798	GNRHR	Gain	10.16 μM
TOX21_KISS1R_HEK293_Agonist	Kidney	Human	84634	KISS1R	Gain	26.96 μM
TOX21_KISS1R_HEK293_WT	Kidney	Human	84634	KISS1R	Gain	17.56 μM

No ToxCast endpoints for intended target type: Molecular messenger

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	0.01 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist	Bone	Human	367	AR	Gain	0.0 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist	Bone	Human	367	AR	Loss	0.08 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist	Bone	Human	367	AR	Gain	0.0 μM
APR_HepG2_StressKinase_24hr	Liver	Human	3725	JUN	Activatory	3.39 μM
APR_HepG2_MitoticArrest_72hr	Liver	Human	3020	H3-3A	Activatory	0.04 μM
APR_HepG2_P-H2AX_72hr	Liver	Human	3014	H2AX	Inhibitory	0.01 μM
APR_HepG2_p53Act_72hr	Liver	Human	7157	TP53	Activatory	0.03 μM
OT_FXR_FXRSRC1_1440	Kidney	Human	6714\|9971	SRC\|NR1H4	Gain	81.99 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	9.26 μM
TOX21_FXR_BLA_Agonist_ratio	Kidney	Human	9971	NR1H4	Gain	32.1 μM
TOX21_PPARd_BLA_Agonist_ratio	Kidney	Human	5467	PPARD	Gain	6.36 μM
TOX21_PPARg_BLA_Antagonist_ratio	Kidney	Human	5468	PPARG	Loss	0.04 μM
TOX21_p53_BLA_p2_ratio	Intestinal	Human	7157	TP53	Gain	46.04 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	28.63 μM
TOX21_p53_BLA_p4_ratio	Intestinal	Human	7157	TP53	Gain	25.56 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	31.83 μM
TOX21_ESRE_BLA_Agonist_ratio	Cervix	Human	22926	ATF6	Gain	16.72 μM
TOX21_NFkB_BLA_agonist_ratio	Cervix	Human	4790	NFKB1	Gain	7.0 μM
TOX21_RXR_BLA_Agonist_ratio	Kidney	Human	6256	RXRA	Gain	0.01 μM
TOX21_TSHR_wt_HTRF_Agonist_ratio	Kidney	Human	7253	TSHR	Gain	14.71 μM
TOX21_p53_BLA_p7_ratio	Intestinal	Human	7157	TP53	Gain	18.39 μM
TOX21_HSE_BLA_Agonist_ratio	Cervix	Human	3297	HSF1	Gain	38.31 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	19.37 μM
TOX21_FXR_BLA_Agonist_ratio	Kidney	Human	9971	NR1H4	Gain	23.74 μM
TOX21_PPARd_BLA_Agonist_ratio	Kidney	Human	5467	PPARD	Gain	6.8 μM
TOX21_PPARg_BLA_Antagonist_ratio	Kidney	Human	5468	PPARG	Loss	0.08 μM
TOX21_p53_BLA_p2_ratio	Intestinal	Human	7157	TP53	Gain	31.83 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	18.31 μM
TOX21_p53_BLA_p4_ratio	Intestinal	Human	7157	TP53	Gain	19.21 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	36.48 μM
TOX21_ESRE_BLA_Agonist_ratio	Cervix	Human	22926	ATF6	Gain	28.18 μM
TOX21_NFkB_BLA_agonist_ratio	Cervix	Human	4790	NFKB1	Gain	9.17 μM
TOX21_H2AX_HTRF_CHO_Agonist_ratio	Ovary	Chinese hamster	3014	H2AX	Gain	0.16 μM
TOX21_TSHR_wt_HTRF_Agonist_ratio	Kidney	Human	7253	TSHR	Gain	7.9 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	0.14 μM
TOX21_p53_BLA_p7_ratio	Intestinal	Human	7157	TP53	Gain	22.51 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.